Enterprise Value
31.48M
Cash
152.5M
Avg Qtr Burn
-43.94M
Short % of Float
0.70%
Insider Ownership
31.08%
Institutional Own.
24.70%
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
CUTX-101 (Copper Histidinate) Details Menkes Disease , Blood cancer | NDA Submission | |
CAEL-101 Details Amyloid light chain amyloidosis | Phase 3 Interim Update | |
Triplex Details Cytomegalovirus | Phase 2 Data readout | |
CEVA-101 Details Traumatic brain injury | Failed Discontinued |